p = #.# [003]

Related by string. p = #.# [002] * PS . PD . Ping . Ps . Per : P aul . & P . Per Cent Stake . Ten Per Cent . Earnings Per Share / = [031] . = [003] . = [019] . = [035] . = [047] : Yard Freestyle =-#.# mg dL . = js enabled . 1 = .# . target = blank . root = string / #.# [010] . #.# [009] . #.# [027] . #.# [022] . #.# [043] : #.# ov #-# . Rs #.# [005] . #.# Advocate promote . #.# Promote sexually . #.# ERA * *

Related by context. Frequent words. (Click for all words.) 70 % CI #.#-#.# [007] 68 P = .# 68 % CI #.#-#.# [003] 67 biochemical recurrence 67 CI #.#-#.# [002] 67 CI -#.# 66 confidence interval CI 66 univariate analysis 66 serum PSA 66 % CI #.#-#.# [006] 64 confidence interval #.#-#.# 64 pg mL 64 estimated glomerular filtration 64 mg kg dose 63 % CI #.#-#.# [002] 63 EBRT 63 PCa 63 glomerular filtration rate 63 nonsignificant 63 Postoperative 63 statistically significant p = 62 HbA 1c 62 fibrinolysis 62 chlorambucil 62 statistically significant p 62 serum concentrations 62 virologic response 62 placebo p = 62 pg ml 62 achieved statistical significance 61 mRCC 61 annualized relapse 61 platelet inhibition 61 nephrectomy 61 left ventricular systolic 61 daunorubicin 61 HBV DNA 61 cirrhotic patients 61 virologic failure 61 p = 61 androgen deprivation 61 sensitivity specificity 61 distant metastasis 61 univariate 61 p = #.# [004] 61 irbesartan 61 apolipoprotein B 61 serum calcium 60 multivariate analyzes 60 μg kg 60 thromboembolism 60 chemoradiotherapy 60 serum sodium 60 composite endpoint 60 HbA1c levels 60 cerebral infarction 60 Natalizumab 60 infarct size 60 concomitant medications 60 neoplasm 60 CMV infection 60 colorectal adenomas 60 Secondary endpoints included 60 cardiac dysfunction 60 HbA1C 60 serum uric acid 60 nonadherence 60 nonobese 59 MetS 59 antibody titers 59 hypoxemia 59 mycophenolate mofetil 59 unfractionated heparin 59 FOLFIRI 59 creatinine levels 59 breast carcinoma 59 p = #.# [002] 59 pheochromocytoma 59 eGFR 59 DOXIL 59 nonresponders 59 abciximab 59 D dimer 59 CI = 59 haematological 59 prespecified 59 enalapril 59 Secondary endpoints include 59 thromboembolic events 59 lymphopenia 59 nonoperative 59 liver transplant recipients 59 mitoxantrone 59 hypoglycemic events 59 ANOVA 59 laboratory abnormalities 59 LVEF 58 alkaline phosphatase 58 neoplasia 58 glycemia 58 cystectomy

Back to home page